Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug

Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is plotting a major fundraise. The Framingham, MA-based biotech outlined an up to $500 million ...